Biotech · Private company
NS Pharma, Inc.
Track this companyFree. Adds NS Pharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials115 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- ViltolarsenPhase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- Best Available TherapyPhase 2 · Primary MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- NS-018Phase 2 · Primary MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- NS-050/NCNP-03Phase 2 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- NS-065/NCNP-01Phase 2 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- NS-089/NCNP-02Phase 2 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- NS-229Phase 2 · Eosinophilic Granulomatosis With PolyangiitisClinicalTrials.gov · fetched Nov 12, 2026
- NS-863 High DosePhase 2 · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)ClinicalTrials.gov · fetched Nov 12, 2026
- NS-863 Low DosePhase 2 · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)PHASE2 · RECRUITING · started Sep 28, 2026ClinicalTrials.gov NCT07441278 · fetched Nov 12, 2026
- NS-050/NCNP-03 in Boys With DMD (Meteor50)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 18, 2024ClinicalTrials.gov NCT06053814 · fetched Nov 12, 2026
- NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 22, 2024ClinicalTrials.gov NCT05996003 · fetched Nov 12, 2026
- Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With PolyangiitisPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 20, 2023ClinicalTrials.gov NCT06046222 · fetched Nov 12, 2026
- Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With MyelofibrosisPHASE2 · TERMINATED · started Jan 31, 2023ClinicalTrials.gov NCT04854096 · fetched Nov 12, 2026
- Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)PHASE2 · COMPLETED · started Jul 1, 2021ClinicalTrials.gov NCT04956289 · fetched Nov 12, 2026
- Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)PHASE4 · ACTIVE_NOT_RECRUITING · started Jun 10, 2021ClinicalTrials.gov NCT04687020 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)PHASE3 · COMPLETED · started Apr 14, 2020ClinicalTrials.gov NCT04060199 · fetched Nov 12, 2026
- Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)PHASE2 · COMPLETED · started Jul 6, 2017ClinicalTrials.gov NCT03167255 · fetched Nov 12, 2026
- Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)PHASE2 · COMPLETED · started Dec 1, 2016ClinicalTrials.gov NCT02740972 · fetched Nov 12, 2026
- Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFPHASE1_PHASE2 · COMPLETED · started Jun 1, 2011ClinicalTrials.gov NCT01423851 · fetched Nov 12, 2026